Mannose
Orphan DrugInvestigational
Description
D-mannose is a simple sugar being investigated as a therapeutic substrate for congenital disorders of glycosylation (CDG), including ALG1-CDG. Oral mannose supplementation may bypass certain enzymatic defects in the N-glycosylation pathway and improve protein glycosylation. Clinical trials have shown potential benefit in some CDG subtypes with improvements in biochemical markers and clinical symptoms.
Indications & Therapeutic Use
Congenital disorders of glycosylation (ALG1-CDG, PMM2-CDG)
Linked Diseases:
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Mannose
| Generic Name | mannose |
| Active Ingredient | D-mannose |
| Drug Class | Congenital disorders of glycosylation (ALG1-CDG |
| Manufacturer | Various |
| Dosage Forms | Oral powder for solution; Oral capsule 500mg |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | Investigational |
| Clinical Trial | NCT02870426 |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes